The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

A new study suggests that a pill used for emergency contraception could be repurposed at a higher dose as an abortion drug, ...

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

The U.S. Department of Health and Human Services has paused public communications until Feb. 1 as Trump appointees take control of health agencies.

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

J&J’s 2025 results will be the launching point for its guidance of 5%-7% revenue growth for 2025-30, which is still well ...

Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will ...